X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2673) 2673
female (1931) 1931
male (1826) 1826
animals (1244) 1244
bisphenol a (1089) 1089
benzhydryl compounds - adverse effects (1073) 1073
benzhydryl compounds - therapeutic use (1041) 1041
adult (927) 927
bisphenol-a (910) 910
middle aged (883) 883
benzhydryl compounds (823) 823
phenols - toxicity (819) 819
toxicology (610) 610
benzhydryl compounds - toxicity (580) 580
phenols (571) 571
aged (554) 554
benzhydryl compounds - administration & dosage (533) 533
environmental sciences (531) 531
treatment outcome (524) 524
pharmacology & pharmacy (523) 523
diabetes mellitus, type 2 - drug therapy (520) 520
pregnancy (495) 495
exposure (486) 486
double-blind method (456) 456
rats (456) 456
double-blind (452) 452
benzhydryl compounds - pharmacology (449) 449
mice (433) 433
glucosides - therapeutic use (431) 431
endocrinology & metabolism (429) 429
analysis (422) 422
dose-response relationship, drug (422) 422
phenols - adverse effects (363) 363
endocrine system (349) 349
endocrine disruptors (341) 341
hypoglycemic agents - therapeutic use (337) 337
type 2 diabetes (337) 337
diabetes (336) 336
modafinil (320) 320
glucose (315) 315
research (312) 312
adolescent (308) 308
glucosides - adverse effects (307) 307
tolterodine tartrate (306) 306
endocrine disruptors - toxicity (304) 304
public, environmental & occupational health (275) 275
risk factors (265) 265
dapagliflozin (258) 258
sodium-glucose transporter 2 - antagonists & inhibitors (255) 255
young adult (251) 251
health aspects (249) 249
hormones, hormone substitutes, and hormone antagonists (240) 240
efficacy (238) 238
urogenital system (236) 236
hypoglycemic agents - adverse effects (234) 234
care and treatment (230) 230
central nervous system stimulants - therapeutic use (227) 227
safety (226) 226
estrogen (219) 219
phenols - urine (219) 219
drug therapy, combination (207) 207
studies (204) 204
in-vitro (201) 201
phenols - pharmacology (201) 201
muscarinic antagonists - therapeutic use (199) 199
drug therapy (197) 197
phenols - analysis (197) 197
diabetes mellitus (196) 196
child (193) 193
time factors (193) 193
cresols - therapeutic use (191) 191
glucosides - administration & dosage (187) 187
central nervous system stimulants - adverse effects (186) 186
endocrine-disrupting chemicals (186) 186
chemicals (184) 184
medicine, general & internal (183) 183
psychiatry (183) 183
empagliflozin (181) 181
overactive bladder (181) 181
urology & nephrology (180) 180
environmental exposure - adverse effects (179) 179
expression (179) 179
metformin (179) 179
benzhydryl compounds - urine (175) 175
environmental health (175) 175
urinary bladder, overactive - drug therapy (175) 175
perinatal exposure (174) 174
risk assessment (174) 174
internal medicine (173) 173
benzhydryl compounds - pharmacokinetics (172) 172
muscarinic antagonists - adverse effects (172) 172
neurosciences (171) 171
clinical trials (170) 170
risk (169) 169
abridged index medicus (168) 168
dextrose (167) 167
diabetes mellitus, type 2 - blood (167) 167
randomized controlled trials as topic (166) 166
toxicity (166) 166
insulin (165) 165
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3536) 3536
German (31) 31
Japanese (27) 27
Chinese (21) 21
Spanish (18) 18
French (13) 13
Russian (13) 13
Swedish (7) 7
Polish (4) 4
Portuguese (4) 4
Czech (3) 3
Danish (3) 3
Bulgarian (2) 2
Italian (2) 2
Slovenian (2) 2
Dutch (1) 1
Hungarian (1) 1
Norwegian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature biotechnology, ISSN 1546-1696, 2009, Volume 28, Issue 1, pp. 63 - 70
... (I-max similar to 80-90%). These allosteric modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active site-directed PDE4 inhibitors, while maintaining biological activity in cellular and in vivo models... 
CAMP-SPECIFIC PHOSPHODIESTERASE | PHOSPHORYLATION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | PROTEIN-KINASE | GENE COMPOSER | SUNCUS-MURINUS | AMP-SPECIFIC PHOSPHODIESTERASE | INHIBITORS | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE | ROLIPRAM BINDING | ANTIDEPRESSANT DRUGS | Phosphodiesterase Inhibitors - therapeutic use | Phosphodiesterase Inhibitors - adverse effects | Humans | Molecular Sequence Data | Crystallography, X-Ray | Structure-Activity Relationship | Benzhydryl Compounds - chemistry | Benzhydryl Compounds - adverse effects | Phenylurea Compounds - adverse effects | Phenylurea Compounds - chemistry | Drug Design | Phosphodiesterase 4 Inhibitors | Behavior, Animal - drug effects | Biological Assay | Phosphodiesterase Inhibitors - chemistry | Benzhydryl Compounds - therapeutic use | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Disease Models, Animal | Allosteric Regulation - drug effects | Protein Structure, Tertiary | Amino Acid Sequence | Cell Line | Catalytic Domain | Models, Molecular | Phenylurea Compounds - therapeutic use | Phosphodiesterase Inhibitors - pharmacology | Vomiting - drug therapy | Cognition - drug effects | Animals | Benzhydryl Compounds - pharmacology | Mice | Phenylurea Compounds - pharmacology | Kinetics | Care and treatment | Schizophrenia | Physiological aspects | Genetic aspects | Cellular signal transduction | Cyclic adenylic acid | Research | Phosphodiesterases | Enzymes | Biotechnology | Cellular biology | Molecular biology | Cognitive ability | Crystal structure | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 380, Issue 4, pp. 347 - 357
.... The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke... 
MORTALITY | 2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Life Sciences | Food and Nutrition | Animal biology | Cellular Biology | Pharmaceutical sciences | Cardiovascular Diseases | drug therapy | Benzhydryl Compounds | complications | Sodium-Glucose Transporter 2 Inhibitors | Hospitalization | prevention & control | Klinisk medicin | Diabetes Mellitus | etiology | Clinical Medicine | epidemiology | statistics & numerical data | adverse effects | mortality | Type 2 | Heart Failure | therapeutic use | Glucosides
Journal Article
Diabetes (New York, N.Y.), ISSN 1939-327X, 2016, Volume 65, Issue 5, pp. 1190 - 1195
Pharmacologically induced glycosuria elicits adaptive responses in glucose homeostasis and hormone release. In type 2 diabetes (T2D), along with decrements in... 
INSULIN | SGLT2 | ENDOCRINOLOGY & METABOLISM | Glucose Intolerance - metabolism | Glycosuria - chemically induced | Carbohydrate Metabolism - drug effects | Lipolysis - drug effects | Benzhydryl Compounds - administration & dosage | Humans | Glucagon-Like Peptide 1 - blood | Diabetes Mellitus, Type 2 - metabolism | Insulin - blood | Glucagon - blood | Glucose Intolerance - blood | Glucose Intolerance - drug therapy | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Time Factors | Glucosides - therapeutic use | C-Reactive Protein - analysis | Benzhydryl Compounds - therapeutic use | Insulin Secretion | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | 3-Hydroxybutyric Acid - blood | Sodium-Glucose Transporter 2 - metabolism | Glucose Intolerance - urine | 3-Hydroxybutyric Acid - agonists | Renal Elimination - drug effects | Sodium-Glucose Transporter 2 Inhibitors | Membrane Transport Modulators - administration & dosage | Diabetes Mellitus, Type 2 - urine | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Algorithms | Glucosides - administration & dosage | 3-Hydroxybutyric Acid - metabolism | Lipid Metabolism - drug effects | Membrane Transport Modulators - therapeutic use | Glucagon - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Hypoglycemic Agents - adverse effects | Energy Metabolism - drug effects | Type 2 diabetes | Care and treatment | Glucagon | Dosage and administration | Triglycerides | Research | Insulin
Journal Article
The lancet. Diabetes & endocrinology, ISSN 2213-8587, 2015, Volume 3, Issue 1, pp. 8 - 10
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 4, pp. 323 - 334
Journal Article
Diabetes care, ISSN 1935-5548, 2015, Volume 38, Issue 3, pp. 420 - 428
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 2015, Volume 17, Issue 12, pp. 1180 - 1193
Aims To determine the effects of empagliflozin on blood pressure (BP) and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes mellitus (T2DM... 
cardiovascular disease | type 2 diabetes | SGLT2 inhibitor | phase III study | Phase III study | Type 2 diabetes | Cardiovascular disease | METFORMIN | ADD-ON | CARDIOVASCULAR EVENTS | RISK | MELLITUS | PULSE PRESSURE | ALL-CAUSE MORTALITY | GLUCOSE | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | HEART-RATE | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Male | Risk | Dose-Response Relationship, Drug | Heart Rate - drug effects | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Arteriosclerosis - epidemiology | Hypertension - prevention & control | Vascular Resistance - drug effects | Female | Glucosides - therapeutic use | Blood Pressure - drug effects | Diabetic Angiopathies - prevention & control | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Arteriosclerosis - complications | Arteriosclerosis - prevention & control | Glucosides - administration & dosage | Vascular Stiffness - drug effects | Biomarkers | Hypertension - complications | Diabetic Angiopathies - epidemiology | Aged | Blood Pressure Monitoring, Ambulatory | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Cohort Studies | Hypertension | Care and treatment | Blood pressure | Heart beat | Original
Journal Article
Annals of internal medicine, ISSN 0003-4819, 06/2012, Volume 156, Issue 12, pp. 861 - 874
Background: Urinary incontinence (UI) in women adversely affects quality of life. Purpose: To conduct a systematic literature review of drugs for urgency UI in... 
OVERACTIVE BLADDER SYNDROME | MEDICINE, GENERAL & INTERNAL | DAILY TROSPIUM CHLORIDE | ONCE-DAILY FORMULATION | SELECTIVE RECEPTOR ANTAGONIST | QUALITY-OF-LIFE | RANDOMIZED CONTROLLED-TRIAL | PLACEBO-CONTROLLED TRIAL | EXTENDED-RELEASE TOLTERODINE | ANTIMUSCARINIC AGENT SOLIFENACIN | PATIENT-REPORTED OUTCOMES | Cresols - therapeutic use | Benzilates | Humans | Muscarinic Antagonists - adverse effects | Cresols - adverse effects | Solifenacin Succinate | Pyrrolidines - adverse effects | Muscarinic Antagonists - therapeutic use | Phenylpropanolamine - adverse effects | Phenylpropanolamine - therapeutic use | Pyrrolidines - therapeutic use | Benzhydryl Compounds - adverse effects | Comparative Effectiveness Research | Quinuclidines - therapeutic use | Nortropanes - adverse effects | Mandelic Acids - therapeutic use | Tolterodine Tartrate | Female | Nortropanes - therapeutic use | Mandelic Acids - adverse effects | Benzhydryl Compounds - therapeutic use | Quinuclidines - adverse effects | Benzofurans - therapeutic use | Tetrahydroisoquinolines - adverse effects | Tetrahydroisoquinolines - therapeutic use | Benzofurans - adverse effects | Randomized Controlled Trials as Topic | Urinary Incontinence - drug therapy | Quality of Life | Urinary incontinence | Research | Demographic aspects | Drug therapy | Patient outcomes
Journal Article